Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9169 - 9176 of 12143 results
What questions should executives ask about their D&O insurance following the new DOJ policies?
September 16, 2015| Blog| Viewpoint
The Basics of EB-5 Financing in a Transaction: Treat Your EB-5 Deal like an IPO [VIDEO]
September 16, 2015| Blog| Viewpoint
CPSC Suspends Over 90% of $3.5 Million Civil Penalty Due to Company’s Inability to Pay; phil&teds USA to Pay $200,000
September 16, 2015| Blog| Viewpoint
Medicare to Permit Value-Based Insurance Design in Medicare Advantage Plans
September 16, 2015| Blog| Viewpoint
Executives Should Take a Closer Look at Insurance Coverage after New DOJ Policies
September 16, 2015| Blog| Viewpoint
Mintz's Gerber Recognized for Hult Prize Work
September 15, 2015| Blog| Viewpoint
Lyft Gets Cited by FCC for Robo-Texting
September 15, 2015| Blog| Viewpoint
Energy Technology Industry Events
September 14, 2015| Blog| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts
Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|